---
schema_version: "secwatch.filing_event.v1"
accession: "0001387131-23-010995"
form_type: "8-K"
ticker: null
cik: "0000887247"
company_name: "DMK PHARMACEUTICALS Corp"
filed_at: "2023-09-08T23:59:59+00:00"
generated_at: "2026-06-10T22:27:38.385197+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Adamis Pharma changes name to DMK Pharmaceuticals, ticker to DMK, pivots to substance use disorders

## Summary
- Adamis Pharmaceuticals renamed DMK Pharmaceuticals effective September 6, 2023; new Nasdaq ticker 'DMK' begins September 8, 2023.
- Strategic focus shifts to small-molecule therapies for substance use disorders, including opioid overdose treatment ZIMHI® and clinical compound DPI-125.
- DPI-125 targets opioid use disorder and moderate-to-severe pain; company expects milestones by end 2024 including transdermal delivery, safety study, and abuse liability study.
- No stockholder vote required; CUSIP unchanged; no impact on existing shareholder rights.

## SEC filing metadata
- accession: 0001387131-23-010995
- form_type: 8-K
- cik: 0000887247
- company_name: DMK PHARMACEUTICALS Corp
- filed_at: 2023-09-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887247/000138713123010995/0001387131-23-010995-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887247/000138713123010995/dmk-8k_090623.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001387131-23-010995
- JSON: https://secwatch.observer/filing/0001387131-23-010995.json
- Plain text: https://secwatch.observer/filing/0001387131-23-010995.txt

## Key facts
- Governance Changes
  DMK PHARMACEUTICALS Corp: Company changed its corporate name from Adamis Pharmaceuticals Corporation to DMK Pharmaceuticals Corporation via a certificate of amendment to the restated certificate of incorporation (effective 2023-09-06).
  - Change: charter amendment
  - Effective: 2023-09-06
  source text: Effective September 6, 2023, Adamis Pharmaceuticals Corporation (the “Company”) changed its corporate name to DMK Pharmaceuticals Corporation (the “Name Change”) pursuant to a certificate of amendment to the Company’s restated certificate of incorporation (the “Charter Amendment”) filed with the Secretary of State of Delaware.
  evidence_url: https://www.sec.gov/Archives/edgar/data/887247/000138713123010995/0001387131-23-010995-index.htm
- Governance Changes
  DMK PHARMACEUTICALS Corp: Amended and restated its Amended and Restated Bylaws to reflect the name change to DMK Pharmaceuticals Corporation (effective 2023-09-06).
  - Change: bylaw amendment
  - Effective: 2023-09-06
  source text: On the effective date of the Name Change the Company also amended and restated its Amended and Restated Bylaws (the “Amended and Restated Bylaws”), to reflect the Name Change.
  evidence_url: https://www.sec.gov/Archives/edgar/data/887247/000138713123010995/0001387131-23-010995-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.